Business Context and Reporting Period
This Form 6-K filing by Alterity Therapeutics Ltd (ASX: ATH, NASDAQ: ATHE) covers the month of June 2019, specifically dated June 4, 2019. The filing incorporates an investor presentation delivered at the Finance News Network conference in Sydney. Alterity is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, with its lead candidate, PBT434, targeting Multiple System Atrophy (MSA) and other atypical parkinsonian disorders.
Key Financial Metrics
The filing provides limited financial data, primarily derived from the investor presentation slides rather than audited financial statements.
- Net Cash: $8.9 million as of March 31, 2019.
- Recent Capital Raise: Approximately A$44 million in strategic investment led by Life Biosciences LLC, with $11.4 million noted as additional funds.
- Market Capitalization: Approximately $30 million (based on a share price of $0.035 as of May 31, 2019).
- Shares Outstanding: 860,837,432 ordinary shares.
- Revenue/Profit: The filing does not provide specific revenue, profit, or cash flow figures for the reporting period, consistent with a pre-revenue clinical-stage company.
Material Changes and Clinical Progress
The primary material update concerns the advancement of the Phase 1 clinical trial program for PBT434.
- Clinical Data: Results from the Phase 1 trial indicate PBT434 is well-tolerated with adverse event rates comparable to placebo. No serious adverse events were reported, and no subjects discontinued dosing due to adverse events.
- Blood-Brain Barrier: Data confirms PBT434 crosses the blood-brain barrier in humans, achieving brain concentrations exceeding those associated with efficacy in animal models.
- Regulatory Status: The company received FDA Orphan Drug Designation for PBT434 for the treatment of MSA in January 2019, granting potential seven-year market exclusivity and development incentives.
- Strategic Investment: The company secured significant funding to accelerate development through the end of Phase 2.
Outlook, Risks, and Management Commentary
Management, led by CEO Geoffrey Kempler, emphasizes the unmet medical need in MSA, a rapidly progressive disorder with no approved treatments. The company projects a potential commercial opportunity of $505 million to $757 million in the U.S. market for MSA alone.
- Development Path: The Phase 1 program is nearing completion. The company intends to proceed with development for MSA as the first therapeutic target.
- Forward-Looking Statements: The filing includes standard disclaimers regarding risks such as difficulties in financing, delays in clinical trials, regulatory approval uncertainties, and the potential for inadequate therapeutic efficacy or unexpected adverse side effects.
- Contingencies: Future success depends on the ability to procure additional financing and the successful execution of clinical trials.
Investor Verification Checklist
- Verify the exact closing date and total proceeds of the A$44 million capital raise led by Life Biosciences LLC.
- Confirm the specific timeline for the completion of the Phase 1 trial and the initiation of Phase 2 trials for MSA.
- Review the full text of the FDA Orphan Drug Designation letter to confirm the scope of exclusivity and incentives.
- Assess the company's cash burn rate to determine if the current net cash position ($8.9M) plus new funding is sufficient to reach Phase 2 milestones.
- Examine the detailed safety data from the Phase 1 trial to validate the claim of "no serious adverse events."